European Leukemia Trial Registry
Trial: EUREKA

More Details
Title Registry in the ELN for CP-CML patients after two years of therapy with tyrosine kinase inhibitors
Scientific Title EUropean survey on the assessment of deep molecular REsponse in chronic phase CML patients after at least two years of therapy with tyrosine KinAse inhibitors
Short Title EUREKA
Trialgroup NN
Type of Trial Epidemiological Registry
Disease Chronic myeloid leukemia(CML) Chronic Phase
Age >= 18 years
Status Active
Start of Recruitment 01.09.2014
Leader Hochhaus, Prof. Dr. med., Andreas
Shortprotocol Shortprotocol
Remark Adult chronic phase BCR-ABL+ CML patients under treatment with TKIs at any prescribed dose will be enrolled. Patients must have received TKI treatment for a minimum of 24 months at registry entry. http://www.eutos.org/content/path_to_cure/eureka/index_eng.html
created 17.09.2014 Sina Hehn
changed 09.11.2015 Zenawit Krüger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org